Esomeprazole or Famotidine in the Management of Aspirin Related Non-Ulcer Dyspepsia
Status:
Unknown status
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
Aspirin can prevent ischemic vascular disease but is commonly complicated by dyspepsia in 30%
of patients. Patients, who have aspirin related dyspepsia, commonly underwent upper endoscopy
to exclude peptic ulcer disease or gastric cancers. For those without significant lesions in
the stomach and duodenum (non-ulcer dyspepsia), the best approach in the management is
unclear. The objective of this study is to compare the efficacy of esomeprazole and
famotidine in the control of dyspeptic symptom. After giving consent, patients will be
randomised to receive either esomeprazole 20 mg daily or famotidine 40 mg daily in a double
blinded manner. The patient will be followed-up at the 2nd and 4th week. The study will be
completed at the 4th week. The primary analysis will be the efficacy in the control of
dyspepsia symptom between the two groups.